Fig. 1 | Scientific Reports

Fig. 1

From: Topical application of the HSP90 inhibitor 17-AAG reduces skin inflammation and partially restores microbial balance: implications for atopic dermatitis therapy

Fig. 1

Topical 17-AAG treatment reduces disease activity in an experimental mouse model of DNCB-induced human-like AD. (a) Schematic representation of experimental design. AD-like skin inflammation was induced in female BALB/c mice by dinitrochlorobenzene (DNCB) application to the shaved and depilated back skin (day − 1) as follows: 1% DNCB on days 0 and 3, followed by 0.4% DNCB on days 6, 8, 10 and 13. 17-AAG (0.5 µM) or vehicle (DMSO: acetone, 1:40 vol/vol) was applied each day with a 2-h interval to DNCB. (b) Representative images of vehicle- and 17-AAG-treated mice at the end of the 14-day treatment period and clinical disease severity of vehicle and 17-AAG-treated mice represented as cumulative SCORAD index. Data are expressed as mean ± SEM (with individual values) of three independent experiments. **** P < 0.0001.

Back to article page